Phaseline

Companies › Chengdu SciMount Pharmatech

Chengdu SciMount Pharmatech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SMP-656
HER2-targeted antibody-drug conjugate (ADC)
ERBB2Phase 2HER2-positive Breast CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07726342SMP-656Phase 2HER2-positive Breast CancerOncologyJul 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Aston Sci. Shanghai Miracogen SystImmune DualityBio Partner Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.